New Dosing Schedules of Dasatinib for CML and Adverse Event Management
Author Information
Author(s): Wong Siu-Fun
Primary Institution: Western University of Health Sciences, College of Pharmacy, Pomona, CA, USA
Hypothesis
Dasatinib can overcome imatinib resistance in patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Conclusion
Dasatinib is effective for patients with imatinib-resistant or intolerant CML and has a manageable safety profile.
Supporting Evidence
- Dasatinib has 325-fold greater in vitro activity against native BCR-ABL compared to imatinib.
- A Phase III study showed that 100 mg once-daily dasatinib improves the safety profile for patients with chronic phase CML.
- Dasatinib is indicated for the treatment of patients with imatinib-resistant or intolerant CML or Ph+ ALL.
- Adverse events associated with dasatinib are typically mild to moderate and can often be managed with dose adjustments.
Takeaway
Dasatinib is a medicine that helps people with a type of blood cancer when another medicine doesn't work anymore.
Methodology
The study reviewed clinical profiles and dosing schedules of dasatinib in patients with imatinib resistance, focusing on Phase II and III studies.
Potential Biases
Potential bias in reporting due to the involvement of the author in advisory boards for the drug.
Limitations
The study did not evaluate dasatinib in pediatric patients or those with impaired liver or renal function.
Participant Demographics
Median age of patients at CML presentation is 53 years; the disease can affect patients of all ages.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website